• EBpay

    Stock code: 002653.SZ

    Innovation-driven Pipeline

    The Company has more than 20 Class 1 innovative drug projects in clinical development across anesthesia and analgesia, respiratory diseases, chronic metabolic diseases, autoimmune diseases, oncology, and digestive and hepatic diseases. Five Class 1 innovative drugs are moving rapidly toward commercialization.
    Anesthesia and Analgesia Respiratory Disease Chronic Metabolic Diseases Autoimmune Disease Oncology Others

    SISHUNING®

    SISHUNING® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Sedation and anesthesia for non-intubated surgical and diagnostic procedures

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUNING® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Induction and maintenance of general anesthesia

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUNING® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Sedation for patients on mechanical ventilation in intensive care

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUNING® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Pediatric indications (China)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUNING® (HSK3486 Injection)

    Target: Gamma-aminobutyric acid A receptor (GABAa)

    Induction of general anesthesia (US)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SIMEINING®

    SIMEINING® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Diabetic peripheral neuropathic pain (DPNP)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SIMEINING® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Postherpetic neuralgia (PHN)

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SIMEINING® (HSK16149 Capsules)

    Target: Voltage-gated calcium channels (VGCC)

    Central neuropathic pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUJING®

    SISHUJING® (HSK21542 Injection)

    Target: Peripheral kappa-opioid receptor (KOR)

    Postoperative analgesia after abdominal surgery

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    SISHUJING® (HSK21542 Injection)

    Target: Peripheral kappa-opioid receptor (KOR)

    Postoperative analgesia after orthopedic surgery

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK36357

    HSK36357

    Target: AAK1

    Neuropathic pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK55718

    HSK55718

    Target: Nav1.8

    Acute pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched

    HSK51155

    HSK51155

    Target: Nav1.8

    Migraine / Acute pain / Chronic pain

    IND

    Phase 1

    Phase 2

    Phase 3

    NDA

    Launched